Valuation
- Market cap
- 1,106,530,000
- Revenue TTM
- $0
- Net income TTM
- $-109,167,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 276,500
- Avg volume
- —
- Day's range
- $15.67 – $16.90
- Shares out
- 66,299,000
- Stochastic %K
- 4%
- Beta
- —
- Analysts
- Strong Sell
- Price target
- $52.25
Company profile
Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. The company's pipeline includes LTG-001, an oral NaV1.8 inhibitor designed to provide fast-acting, opioid-sparing relief for the treatment of acute pain; LTG-321, a NaV1.8 inhibitor candidate developed for the treatment of chronic musculoskeletal pain, starting with osteoarthritis;...
Show more
Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. The company's pipeline includes LTG-001, an oral NaV1.8 inhibitor designed to provide fast-acting, opioid-sparing relief for the treatment of acute pain; LTG-321, a NaV1.8 inhibitor candidate developed for the treatment of chronic musculoskeletal pain, starting with osteoarthritis; and LTG-418, a NaV1.8 inhibitor developed for the treatment of acute and chronic pain. Latigo Biotherapeutics, Inc. was formerly known as WVB-Desmond, Inc. and changed its name to Latigo Biotherapeutics, Inc. in March 2019. Latigo Biotherapeutics, Inc. was incorporated in 2018 and is based in Thousand Oaks, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 805 716 2927
- Website
- https://latigobio.com
- Address
- 1300 Rancho Conejo Boulevard, Suite 305, Thousand Oaks, United States
Latest news
No headlines yet.
